Our pipeline
From discovery to market, the progress of our Targeted Active Therapy against myasthenia gravis, in human and veterinary medicine.
Completed step
Current step
Coming soon
Human development
CuraVac · targeted active therapies
CV-MG
Myasthenia gravis (CV-MG01 → CV-MG02)
EMA orphan · 2009
FDA orphan · 2011
View the Phase 1b results (PDF)
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Market
Veterinary development
Veterinary Unit · CV-MG01 · myasthenia gravis in companion animals
Discover the Veterinary UnitCanine MG therapy
Canine myasthenia gravis
75 % remission
Research
Proof of efficacy
Limited Markets
Positive EMA report
Market
Supporting the transition to Phase 2
A de-risked program — successful Phase 1b, orphan drug designations, animal validation — ready to accelerate.